Filing Details
- Accession Number:
- 0001104659-22-092614
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-18 17:15:38
- Reporting Period:
- 2022-08-16
- Accepted Time:
- 2022-08-18 17:15:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1356576 | Supernus Pharmaceuticals Inc. | SUPN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1539937 | A. Jack Khattar | C/O Supernus Pharmaceuticals, Inc. 9715 Key West Avenue Rockville MD 20850 | President, Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-08-16 | 39,530 | $0.00 | 799,431 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-16 | 9,182 | $34.01 | 790,249 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-16 | 14,690 | $34.01 | 775,559 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Appreciation Right | Disposition | 2022-08-16 | 39,530 | $0.00 | 39,530 | $7.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,895 | 2023-02-05 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,047,700 | Indirect | By the KBT Trust |
| Common Stock | 4,000 | Indirect | By son |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.
- Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.07, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
- The stock appreciation right vested in four equal annual installments beginning on February 5, 2014.
Billionaire Hedge Funds
